{"entity":{"id":"nct05060276","kind":"trial","name":"Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is withdrawn.","summary":"The registry lists NCT05060276 as withdrawn, last updated 2023-01-26. Enrolment is 0 actual participants. Interventions: STI-3258. Primary measures include Incidence of adverse events by type, frequency, severity, and causality (safety); Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety). The registry reason for stopping is: Protocol changed to Phase 2 No results are posted in the registry; this does not exclude separate publications.","status":"withdrawn","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05060276","url":"https://clinicaltrials.gov/study/NCT05060276"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["sti-3258"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05060276","phase":"1","setting":"A Phase 1B, Dose-Escalation Study of the Safety and Preliminary Efficacy of an Anti-Trop2 Antibody Drug Conjugate (STI-3258) in Patients With Relapsed or Refractory Solid Tumors","sponsor":"Sorrento Therapeutics, Inc.","started":"2022-12","startedType":"estimated","enrolled":0,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05060276/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"sti-3258","kind":"drug","name":"STI-3258","route":"/drugs/sti-3258/"}]}}